Investor Presentaiton

. . Strategies by Business Diagnostics (Japan) Blood Coagulation: Introduce and expand sales of new blood coagulation testing equipment • Immunology: Enter high-sensitivity fields through external fusion • Diabetes: Expand alliances Net sales (JPY billion) Medical Business SEKISUI . . Diagnostics (overseas) Overseas testing system Europe and the Americas: Drive growth by entering the OTC market and expanding proprietary product (gene testing) launch areas China: Promote domestic production; strengthen alliances Asia: Bring new PCR products to the market; enter POC and coagulation markets Net sales (JPY billion) 28.5 30.9 31.6 33.6 FY19 FY22 FY23 Plan FY25 Medium-term Plan • . Pharmaceutical Sciences (Pharmaceutical and Fine Chemicals, Drug Development Solutions, Enzymes) Pharmaceutical and Fine Chemicals: Capture new large-scale projects by strengthening the marketing function Enzymes: Expand the CDMO Business through the start of full-fledged operations at a U.K. GMP- compliant facility Net sales (JPY billion) 59.9 41.2 46.5 30.3 FY19 FY22 FY23 Plan FY25 Medium-term Plan New Product Sales Aim to systematically launch new products by strengthening core technologies and acquiring new technologies Pharmaceutical science (CDMO) 24% Net sales 19% 13% Percentage of total Medical Business sales 24% 18% 12% (JPY billion) 19.9 17.6 16.9 13.6 26.6 21.6 16.8 13.8 9.2 10.4 FY19 FY22 FY23 Plan FY25 Medium-term Plan FY19 FY20 FY21 FY22 FY23 Plan FY25 Medium-term Plan Copyright SEKISUI CHEMICAL CO., LTD. 41

View entire presentation